Login to Your Account



Astellas, Pfizer score a win on quest to extend Xtandi's reach

By Michael Fitzhugh
Staff Writer

Thursday, September 14, 2017

Swept ahead of schedule by a summer protocol amendment, a positive phase III trial of Xtandi in men with early stage CRPC is now providing key evidence that could back their inclusion in the drug's label.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription